TXG — Stock Film
STOCK FILMSCENE 1/11TXG · $63.87
Stock Expert AI presents
TXG
10x Genomics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
10x Genomics, Inc. A quick introduction.

On the stock market since 2019, it operates in the world of health and science. It has 1,178 employees. Now — the numbers.

on the stock market since 2019
1,178 employees
$7.1B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 7% a year over the last 4 years. Red columns mark years that ended in a loss.

$490.5M
2021
$516.4M
2022
$618.7M
2023
$610.8M
2024
$642.8M
2025
In the vault right now:
$0
DEBT: $157.7M
At this pace, that money lasts about 12 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
70
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
75
strong

Clearly above the class average — a step short of the very top.

VALUATION
54
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

PRICE MOMENTUM
83
very strong

The stock has been running stronger than the market lately.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
WEAK SPOTS
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 67% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Sales are holding up

The company sells $642.8M a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/2
Strong cash, light debt

There is $523.4M in the vault; even if every debt were paid off, $365.7M would remain.

1
THE RISKS · 1/3
The losses continue

A loss of $43.5M against $642.8M in annual sales.

2
THE RISKS · 2/3
A wildly swinging price

This stock swings about 2 times as much as the market average. Big rallies — and big drops — can both happen fast.

3
THE RISKS · 3/3
The price sits above analysts’ target

The stock trades 24% above the average analyst price target.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, TXG sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: TXG has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film